WO2000038706A3 - Methods for treating cancer and for mediating chemotaxis of dendritic cells - Google Patents

Methods for treating cancer and for mediating chemotaxis of dendritic cells Download PDF

Info

Publication number
WO2000038706A3
WO2000038706A3 PCT/US1999/031096 US9931096W WO0038706A3 WO 2000038706 A3 WO2000038706 A3 WO 2000038706A3 US 9931096 W US9931096 W US 9931096W WO 0038706 A3 WO0038706 A3 WO 0038706A3
Authority
WO
WIPO (PCT)
Prior art keywords
slc
methods
mammal
immune response
variants
Prior art date
Application number
PCT/US1999/031096
Other languages
French (fr)
Other versions
WO2000038706A2 (en
WO2000038706A9 (en
Inventor
Chu Keting
Hong Xin
Vivien W F Chan
Srinivas Kothakota
Lewis T Williams
Jill A Winter
Original Assignee
Chiron Corp
Chu Keting
Hong Xin
Vivien W F Chan
Srinivas Kothakota
Lewis T Williams
Jill A Winter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Chu Keting, Hong Xin, Vivien W F Chan, Srinivas Kothakota, Lewis T Williams, Jill A Winter filed Critical Chiron Corp
Priority to AU27157/00A priority Critical patent/AU2715700A/en
Priority to EP99968968A priority patent/EP1140141A2/en
Priority to JP2000590657A priority patent/JP2002533402A/en
Publication of WO2000038706A2 publication Critical patent/WO2000038706A2/en
Publication of WO2000038706A3 publication Critical patent/WO2000038706A3/en
Publication of WO2000038706A9 publication Critical patent/WO2000038706A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention is based on the novel observation, reported herein, that SLC inhibits the growth of tumors in vivo and is a potent chemokine for Dendritic Cells (DC). Thus, the invention provides a method of treating cancer or hyperproliferative disorder in a mammalian subject, comprising: administering a therapeutically effective amount of an SLC to said subject. SLCs useful in the methods of the invention include SLC polypeptides, variants and fragments and related nucleic acids. The methods of the invention are useful in the treatment of cancer and hyperproliferative disorders. In addition, the invention provides methods for modulating dendritic cell function in a mammal, said method comprising administering a therapeutically effective amount of an SLC agent to said mammal, said agent selected from the group consisting of: SLC plypeptides, SLC polypeptide variants, SLC polypeptide fragments, polynucleotides encoding SLC polypeptides, variants and fragments, anti-SLC antibodies and ligands for the CCR7 receptor. Such methods can be used to increase or decrease an immune response, particularly a primary immune response, in a mammal. The methods are particularly useful in the prevention of graft rejection and in the treatment of autoimmune disease. Alternatively, the methods may be used to enhance an immune response.
PCT/US1999/031096 1998-12-31 1999-12-28 Methods for treating cancer and for mediating chemotaxis of dendritic cells WO2000038706A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU27157/00A AU2715700A (en) 1998-12-31 1999-12-28 Methods for treating cancer and for mediating chemotaxis of dendritic cells
EP99968968A EP1140141A2 (en) 1998-12-31 1999-12-28 Methods for treating cancer and for mediating chemotaxis of dendritic cells
JP2000590657A JP2002533402A (en) 1998-12-31 1999-12-28 Methods for treating cancer and mediating dendritic cell chemotaxis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11449898P 1998-12-31 1998-12-31
US60/114,498 1998-12-31

Publications (3)

Publication Number Publication Date
WO2000038706A2 WO2000038706A2 (en) 2000-07-06
WO2000038706A3 true WO2000038706A3 (en) 2000-11-23
WO2000038706A9 WO2000038706A9 (en) 2002-08-22

Family

ID=22355590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/031096 WO2000038706A2 (en) 1998-12-31 1999-12-28 Methods for treating cancer and for mediating chemotaxis of dendritic cells

Country Status (4)

Country Link
EP (1) EP1140141A2 (en)
JP (1) JP2002533402A (en)
AU (1) AU2715700A (en)
WO (1) WO2000038706A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7005509B1 (en) 1995-02-17 2006-02-28 Incyte Corporation Chemokine PANEC-1 polynucleotides and compositions and methods related thereto
WO2001040311A1 (en) * 1999-11-30 2001-06-07 Shionogi & Co., Ltd. Chemokine slc-il2 fused protein and gene thereof
US7700359B2 (en) 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
US20020168358A1 (en) * 2001-04-30 2002-11-14 Gladue Ronald P. Treatment of T-cell mediated diseases
EP1256354A1 (en) * 2001-05-11 2002-11-13 Schering Corporation Methods for treating cancer
AU2003235791A1 (en) 2002-01-08 2003-07-24 Chiron Corporation Gene products differentially expressed in cancerous breast cells and their methods of use
CA2500661A1 (en) 2002-10-01 2004-04-15 Chiron Corporation Anti-cancer and anti-infectious disease compositions and methods for using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006169A1 (en) * 1994-08-23 1996-02-29 Human Genome Sciences, Inc. Human chemokine beta-9
WO1998014581A1 (en) * 1996-10-02 1998-04-09 Schering Corporation Mammalian chemokines
WO1998031809A1 (en) * 1997-01-20 1998-07-23 Shionogi & Co., Ltd. Human cc chemokine slc
WO2000009151A1 (en) * 1998-08-17 2000-02-24 Schering Corporation Regulation of dendritic cell trafficking

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996006169A1 (en) * 1994-08-23 1996-02-29 Human Genome Sciences, Inc. Human chemokine beta-9
WO1998014581A1 (en) * 1996-10-02 1998-04-09 Schering Corporation Mammalian chemokines
WO1998031809A1 (en) * 1997-01-20 1998-07-23 Shionogi & Co., Ltd. Human cc chemokine slc
WO2000009151A1 (en) * 1998-08-17 2000-02-24 Schering Corporation Regulation of dendritic cell trafficking

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199835, Derwent World Patents Index; Class B04, AN 1998-414107, XP002144766 *
SOTO H ET AL: "The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 95, no. 14, 7 July 1998 (1998-07-07), pages 8205 - 8210, XP002144765 *
WILLIMANN K ET AL: "The chemokine SLC is expressed in T cell areas of lymph nodes and mucosal lymphoid tissues and attracts activated T cells via CCR7", EUROPEAN JOURNAL OF IMMUNOLOGY, vol. 28, no. 6, June 1998 (1998-06-01), pages 2025 - 2034, XP002121901 *

Also Published As

Publication number Publication date
WO2000038706A2 (en) 2000-07-06
AU2715700A (en) 2000-07-31
EP1140141A2 (en) 2001-10-10
WO2000038706A9 (en) 2002-08-22
JP2002533402A (en) 2002-10-08

Similar Documents

Publication Publication Date Title
EP1082433A4 (en) Interleukins-21 and 22
EP2319870A3 (en) Human antibodies that bind human IL-12 and methods for producing
EP1778842B8 (en) Compositions and methods of use for mgd-csf in disease treatment
CY2463B1 (en) Human antibodies that bind human tnfalpha.
EP1006194A3 (en) C-erbB-2 external domain: GP75
ZA958444B (en) Biological active proteins
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
PL340755A1 (en) Polypeptide-10 similar to mammal cytokin
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
CA2296737A1 (en) Ligand for herpes simplex virus entry mediator and methods of use
WO2000038706A3 (en) Methods for treating cancer and for mediating chemotaxis of dendritic cells
EP1674108A3 (en) Osteoporosis treatment
WO2000017235A3 (en) Cytokine receptor zalpha11
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO1998040498A3 (en) Immunoadhesins and methods of production and use thereof
WO1998031795A3 (en) Novel human metallothionein
WO1998011234A3 (en) Human protein kinases
WO1998018822A3 (en) Novel human lim proteins
WO2000028032A3 (en) Human cell surface receptor proteins
WO1998025956A3 (en) Human GTP-binding proteins
EP1443055A3 (en) Interleukins-21 and 22
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
EP0732398A4 (en) Novel tyrosine kinase
WO2001040291A3 (en) Proteins and nucleic acids encoding the same
NZ320932A (en) Short forms of chemokine b-8

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 590657

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999968968

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999968968

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/10-10/10; DUE TO LATE TRANSMITTAL BY THE RECEIVINGOFFICE

WWR Wipo information: refused in national office

Ref document number: 1999968968

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999968968

Country of ref document: EP